(3rd Party Tested in USA) (batch 3/22/2022) click here
We offer the best MK677 for sale in three different forms: capsules, liquid, powder.
Benefits of Ibutamoren (MK677):
1) Helps build muscles and increases bone density
2) Significantly improves Sleep 
3) Has been used in clinical trials for growth hormone deficiency
4) Helps in wound healing and tissue regeneration
Mk677 for sale :
MK-677 is a hormone secretagogue and it is not a Selective Androgen Receptor Modulators (SARMs). MK-677 can be consumed orally, where it mimics the same behavior as the hunger hormone called ghrelin. Thus, the MK-677 elevates the level of growth hormones hGH in the body.
The benefits of MK 677:
The results show that MK-0751 increases growth hormonns (GH) in young male volunteers . The results show that MK 677 increases the level of GH in dogs after oral doses as low as o.125 mg/kg. In , the authors showed a study over a period of one week on seven men who consumed 25mg of MK-677 and the results show that MK-677 causes an increasing of the level of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3). The authors recommended a usage of MK-677 to treat Somatotropic deficiency.
Aging causes a deceasing in IGF-I circulation, increase the level of cortisol in nighttime, and profound in sleeping. This symptoms can reduce the amounts of deeper stages of sleep along with REM sleep. In , the authors strongly recommended the use of MK-677 for sleep disturbance in older adults.
Side effects of MK 677:
The results showed that the release of GH using MK-677 does not significantly affect the plasma level of aldosterone, prolactin, luteinizing hormone, and thyroxine after oral administration of 1mg/kg . The results showed an increase in cortisol. Thus, the MK-677 was selected for clinical studies.
Read More about benefits of MK677
 Salomon F, Cuneo R, Sönksen PH. Growth hormone and protein metabolism. Hormones. 1991;36(Suppl. 1):41-3.
 Merimee TJ, Laron Z, LeRoith D. Growth hormone, IGF-I and growth: new view of old concepts. Freund; 1996.
 Momany FA, Bowers CY, Reynolds GA, Hong A, Newlander K. Conformational energy studies and in vitro and in vivo activity data on growth hormone-releasing peptides. Endocrinology. 1984 May 1;114(5):1531-6.
 Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, Cheng K, Chan WW, Butler B, Hickey G. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences. 1995 Jul 18;92(15):7001-5.
Gertz BJ, Barrett JS, Eisenhandler R, Krupa DA, Wittreich JM, Seibold JR, Schneider SH. Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. The Journal of Clinical Endocrinology & Metabolism. 1993 Nov 1;77(5):1393-7.
 Copinschi GE, Van Onderbergen AN, L'Hermite-Balériaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, De Smet M, Thorner MO, Van Cauter E. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. The Journal of Clinical Endocrinology & Metabolism. 1996 Aug 1;81(8):2776-82.